Movers and SHAKERS
Dyadic International Inc. (DYAI)
C1 Technology to Produce High-Level and Cost-Effective Biologics to Combat Coronavirus
Dyadic International Inc. is a biotechnology company developing a proprietary C1 expression platform to express and manufacture biologic products. The C1 technology is part of a fungi expression system, which utilizes inexpensive substrates yielding a high level of production. Dyadic is currently improving and optimizing the production of biological products in a C1 expression system. The company’s partnership portfolio with pharmaceutical and institutions includes Zapi Project, Israel Institute for Biological Research, Mitsubishi Tanabe Pharma, Sanofi-Aventis covering the production of a diverse range of biologics, such as monoclonal antibodies, bispecific and Fc-fusion proteins. Dyadic also established a sub-licensing agreement with an Australian based drug development and contract manufacturing firm, Luina Bio, to utilize C1 platform for the development and commercialization of biological products to prevent and treat animal diseases. Company’s C1 bioenergy business was sold to Dupond Industrial Biosciences (DuPont) for $75 mm in 2015 granting the company the rights to use C1 platform in biopharma applications.
Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Coronavirus remains to be a major threat to human lives and the economy. The coronavirus pandemic is still a major threat to human lives. The number of confirmed cases reached over 7.1 million and the death attributed to Covid-19 now exceeds 400,000 globally, according to the World Health Organization.
Manufacturing massive amounts of vaccines and antibodies may be an emerging hurdle. The regulatory agencies, biotechnology, and pharmaceuticals world combine efforts to combat coronavirus. The federal government plans to conduct Phase 3 clinical trials to assess vaccine candidates this summer. Many efforts are focused on rapid progress to bring an effective vaccination and treatment method on the market. However, producing massive amounts...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.